ieramilimab development code monoclonal antibody developed novartis treatment cancer antibody targets immune checkpoint expressed cells tends downregulate immune response june presentation novartis management indicated dosing imminent first clinical trials ieramilimabs first clinical trial phase patients various solid tumors combination spartalizumab monoclonal antibody recruiting phase study combination spartalizumab treatment metastatic melanoma httpsenwikipediaorgwikiieramilimab